Prime Medicine, Inc. (PRME)
3.61
+0.48
(+15.34%)
USD |
NASDAQ |
Oct 15, 16:00
3.65
+0.04
(+1.11%)
After-Hours: 20:00
Prime Medicine Cash from Operations (TTM) : -156.05M for June 30, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -156.05M |
| March 31, 2026 | -156.42M |
| December 31, 2025 | -162.56M |
| September 30, 2025 | -109.06M |
| June 30, 2025 | -99.94M |
| March 31, 2025 | -104.02M |
| December 31, 2024 | -122.86M |
| September 30, 2024 | -182.97M |
| June 30, 2024 | -196.23M |
| March 31, 2024 | -191.56M |
| Date | Value |
|---|---|
| December 31, 2023 | -165.41M |
| September 30, 2023 | -152.26M |
| June 30, 2023 | -143.19M |
| March 31, 2023 | -122.60M |
| December 31, 2022 | -131.83M |
| September 30, 2022 | -114.30M |
| June 30, 2022 | -93.81M |
| March 31, 2022 | -80.00M |
| December 31, 2021 | -34.08M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Beam Therapeutics, Inc. | -359.38M |
| Twist Bioscience Corp. | -53.07M |
| Intellia Therapeutics, Inc. | -346.64M |
| Moderna, Inc. | -1.073B |
| Q32 Bio, Inc. | -19.83M |